The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity
Open accessAbstract
Activation of the necroptotic kinases RIPK1 and RIPK3 within the tumor microenvironment enhances immune-mediated tumor control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kearse, M., Moir, R., Wilson, A., Stones-Havas, S., Cheung, M., Sturrock, S., Buxton, S., Cooper, A., Markowitz, S., Duran, C., et al. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts199 · Cited by 20,027
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved vectors and genome-wide libraries for CRISPR screening
Sanjana, N. E., Shalem, O., & Zhang, F. (2014) · Nature Methods · doi:10.1038/nmeth.3047 · Cited by 5,239
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation
Scaffidi, P., Misteli, T., & Bianchi, M. E. (2002) · Nature · doi:10.1038/nature00858 · Cited by 4,221
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
Twyman-Saint Victor, C., Rech, A. J., Maity, A., Rengan, R., Pauken, K. E., Stelekati, E., Benci, J. L., Xu, B., Dada, H., Odorizzi, P. M., et al. (2015) · Nature · doi:10.1038/nature14292 · Cited by 2,434
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death
Casares, N., Pequignot, M. O., Tesniere, A., Ghiringhelli, F., Roux, S., Chaput, N., Schmitt, E., Hamai, A., Hervas-Stubbs, S., Obeid, M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050915 · Cited by 1,512
Spranger, S., Dai, D., Horton, B., & Gajewski, T. F. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.04.003 · Cited by 1,441
Broz, M. L., Binnewies, M., Boldajipour, B., Nelson, A. E., Pollack, J. L., Erle, D. J., Barczak, A., Rosenblum, M. D., Daud, A., Barber, D. L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.09.007 · Cited by 1,207
Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.03.012 · Cited by 1,201
Immunogenic death of colon cancer cells treated with oxaliplatin
Tesniere, A., Schlemmer, F., Boige, V, Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. (2010) · Oncogene · doi:10.1038/onc.2009.356 · Cited by 1,173
Linkermann, A., & Green, D. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1310050 · Cited by 1,103
Introduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J.-N., Moujalled, D. M., et al. (2016) · Nature · doi:10.1038/nature19830 · Cited by 1,047
Necroptosis in development, inflammation and disease
Weinlich, R., Oberst, A., Beere, H. M., & Green, D. R. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.149 · Cited by 1,016
Self-citationIdentification of a dendritic cell receptor that couples sensing of necrosis to immunity
Sancho, D., Joffre, O. P., Keller, A. M., Rogers, N. C., Martínez, D., Hernanz-Falcón, P., Rosewell, I., & Sousa, C. R. E. (2009) · Nature · doi:10.1038/nature07750 · Cited by 750 · cited 2×
“CLEC9A blocking experiments followed the same dosing protocol, using 400 g of -CLEC9A (clone 7H11, Bio X Cell) or isotype control, as described (27).”
BackgroundMethodOncoLnc: linking TCGA survival data to mRNAs, miRNAs, and lncRNAs
Anaya, J. (2016) · PeerJ Computer Science · doi:10.7717/peerj-cs.67 · Cited by 639
Kazama, H., Ricci, J.-E., Herndon, J. M., Hoppe, G., Green, D. R., & Ferguson, T. A. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.013 · Cited by 627
RIPK1 and NF-κB signaling in dying cells determines cross-priming of CD8 + T cells
Yatim, N., Jusforgues-Saklani, H., Orozco, S., Schulz, O., Barreira da Silva, R., Reis e Sousa, C., Green, D. R., Oberst, A., & Albert, M. L. (2015) · Science · doi:10.1126/science.aad0395 · Cited by 622
Self-citationRIP3 Induces Apoptosis Independent of Pronecrotic Kinase Activity
Mandal, P., Berger, S. B., Pillay, S., Moriwaki, K., Huang, C., Guo, H., Lich, J. D., Finger, J., Kasparcova, V., Votta, B., et al. (2014) · Molecular Cell · doi:10.1016/j.molcel.2014.10.021 · Cited by 618
Fernald, K., & Kurokawa, M. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.07.006 · Cited by 579
Initiation and execution mechanisms of necroptosis: an overview
Grootjans, S., Vanden Berghe, T., & Vandenabeele, P. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2017.65 · Cited by 566
Koo, G.-B., Morgan, M. J., Lee, D.-G., Kim, W.-J., Yoon, J.-H., Koo, J. S., Kim, S. I., Kim, S. J., Son, M. K., Hong, S. S., et al. (2015) · Cell Research · doi:10.1038/cr.2015.56 · Cited by 491
Vaccination with Necroptotic Cancer Cells Induces Efficient Anti-tumor Immunity
Aaes, T. L., Kaczmarek, A., Delvaeye, T., De Craene, B., De Koker, S., Heyndrickx, L., Delrue, I., Taminau, J., Wiernicki, B., De Groote, P., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.037 · Cited by 443
Dying cells actively regulate adaptive immune responses
Yatim, N., Cullen, S., & Albert, M. L. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.9 · Cited by 442
Newton, K., Dugger, D. L., Maltzman, A., Greve, J. M., Hedehus, M., Martin-McNulty, B., Carano, R. A. D., Cao, T. C., van Bruggen, N., Bernstein, L., et al. (2016) · Cell Death & Differentiation · doi:10.1038/cdd.2016.46 · Cited by 438
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases
Park, C. G., Hartl, C. A., Schmid, D., Carmona, E. M., Kim, H.-J., & Goldberg, M. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar1916 · Cited by 321
Daniels, B. P., Kofman, S. B., Smith, J. R., Norris, G. T., Snyder, A. G., Kolb, J. P., Gao, X., Locasale, J. W., Martinez, J., Gale, M., et al. (2019) · Immunity · doi:10.1016/j.immuni.2018.11.017 · Cited by 307
Self-citationDe novo design of protein homo-oligomers with modular hydrogen-bond network–mediated specificity
Boyken, S. E., Chen, Z., Groves, B., Langan, R. A., Oberdorfer, G., Ford, A., Gilmore, J. M., Xu, C., DiMaio, F., Pereira, J. H., et al. (2016) · Science · doi:10.1126/science.aad8865 · Cited by 304
Self-citationRIPK1 both positively and negatively regulates RIPK3 oligomerization and necroptosis
Orozco, S., Yatim, N., Werner, M. R., Tran, H., Gunja, S. Y., Tait, S. W., Albert, M. L., Green, D. R., & Oberst, A. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2014.76 · Cited by 294
Self-citationRIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4
Najjar, M., Saleh, D., Zelic, M., Nogusa, S., Shah, S., Tai, A., Finger, J. N., Polykratis, A., Gough, P. J., Bertin, J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.007 · Cited by 284
Apoptosis and Necroptosis as Host Defense Strategies to Prevent Viral Infection
Orzalli, M. H., & Kagan, J. C. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.05.007 · Cited by 238
MLKL Activation Triggers NLRP3-Mediated Processing and Release of IL-1β Independently of Gasdermin-D
Gutierrez, K. D., Davis, M. A., Daniels, B. P., Olsen, T. M., Ralli-Jain, P., Tait, S. W. G., Gale, M., & Oberst, A. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601757 · Cited by 228
Self-citationSather, B. D., Romano Ibarra, G. S., Sommer, K., Curinga, G., Hale, M., Khan, I. F., Singh, S., Song, Y., Gwiazda, K., Sahni, J., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac5530 · Cited by 223
Necroptosis in anti-viral inflammation
Nailwal, H., & Chan, F. K.-M. (2019) · Cell Death & Differentiation · doi:10.1038/s41418-018-0172-x · Cited by 216
Bath-Hextall, F., Ozolins, M., Armstrong, S. J., Colver, G. B., Perkins, W., Miller, P. S. J., & Williams, H. C. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70530-8 · Cited by 213
Remijsen, Q., Goossens, V, Grootjans, S., Van den Haute, C., Vanlangenakker, N., Dondelinger, Y., Roelandt, R., Bruggeman, I., Goncalves, A., Bertrand, M. J. M., et al. (2014) · Cell Death & Disease · doi:10.1038/cddis.2013.531 · Cited by 202
Macrophages use different internalization mechanisms to clear apoptotic and necrotic cells
Krysko, D. V., Denecker, G., Festjens, N., Gabriels, S., Parthoens, E., D'Herde, K., & Vandenabeele, P. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401900 · Cited by 197
AAV-mediated gene targeting methods for human cells
Khan, I. F., Hirata, R. K., & Russell, D. W. (2011) · Nature Protocols · doi:10.1038/nprot.2011.301 · Cited by 188
The AIM2-like Receptors Are Dispensable for the Interferon Response to Intracellular DNA
Gray, E. E., Winship, D., Snyder, J. M., Child, S. J., Geballe, A. P., & Stetson, D. B. (2016) · Immunity · doi:10.1016/j.immuni.2016.06.015 · Cited by 187
Brault, M., Olsen, T. M., Martinez, J., Stetson, D. B., & Oberst, A. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701492 · Cited by 185
Self-citationRIPK3 Restricts Viral Pathogenesis via Cell Death-Independent Neuroinflammation
Daniels, B. P., Snyder, A. G., Olsen, T. M., Orozco, S., Oguin, T. H., Tait, S. W. G., Martinez, J., Gale, M., Loo, Y.-M., & Oberst, A. (2017) · Cell · doi:10.1016/j.cell.2017.03.011 · Cited by 177
Self-citationAkalu, Y. T., Rothlin, C. V., & Ghosh, S. (2017) · Immunological Reviews · doi:10.1111/imr.12522 · Cited by 160
Derakhshan, A., Chen, Z., & Waes, C. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2172 · Cited by 158
Hoecke, L. V., Lint, S. V., Roose, K., Parys, A. V., Vandenabeele, P., Grooten, J., Tavernier, J. H., Koker, S. D., & Saelens, X. (2018) · Nature Communications · doi:10.1038/s41467-018-05979-8 · Cited by 151
Targeted gene editing restores regulated CD40L function in X-linked hyper-IgM syndrome
Hubbard, N., Hagin, D., Sommer, K., Song, Y., Khan, I., Clough, C. A., Ochs, H. D., Rawlings, D. J., Scharenberg, A. M., & Torgerson, T. R. (2016) · Blood · doi:10.1182/blood-2015-11-683235 · Cited by 142
Self-citationComparing the effects of different cell death programs in tumor progression and immunotherapy
Messmer, M. N., Snyder, A. G., & Oberst, A. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0214-4 · Cited by 109
Self-citationLee, B. H., Hwang, D. M., Palaniyar, N., Grinstein, S., Philpott, D. J., & Hu, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035812 · Cited by 102
Kinase Activities of RIPK1 and RIPK3 Can Direct IFN-β Synthesis Induced by Lipopolysaccharide
Saleh, D., Najjar, M., Zelic, M., Shah, S., Nogusa, S., Polykratis, A., Paczosa, M. K., Gough, P. J., Bertin, J., Whalen, M. J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601717 · Cited by 57
Caspase inhibitors: a review of recently patented compounds (2013-2015)
Lee, H., Shin, E. A., Lee, J. H., Ahn, D., Kim, C.-G., Kim, J., & Kim, S. (2017) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1378426 · Cited by 57
Radiotherapy and immune checkpoint blockade: potential interactions and future directions
Binder, D. C., Fu, Y., & Weichselbaum, R. R. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.05.007 · Cited by 33
Bosurgi, L., Hughes, L. D., Rothlin, C. V., & Ghosh, S. (2017) · Immunological Reviews · doi:10.1111/imr.12585 · Cited by 32
Cited by
Inflammation and cancer: triggers, mechanisms, and consequences
Greten, F. R., & Grivennikov, S. I. (2019) · Immunity · doi:10.1016/j.immuni.2019.06.025 · Cited by 3,806
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Tang, R., Xu, J., Zhang, B., Liu, J., Liang, C., Hua, J., Meng, Q., Yu, X., & Shi, S. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00946-7 · Cited by 1,273
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, X., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,042
Targeting immunogenic cell death in cancer
Ahmed, A., & Tait, S. W. G. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12851 · Cited by 930
Metadata
- Authors
- Snyder, A. G., Hubbard, N. W., Messmer, M. N., Kofman, S. B., Hagan, C. E., Orozco, S. L., Chiang, K., Daniels, B. P., Baker, D., & Oberst, A.
- Venue
- Science Immunology
- Published
- 2019-06-07
- Volume
- 4
- Issue
- 36
- ISSN
- 2470-9468 (ISSN-L)
- OpenAlex
- W2950635392
- Cited by
- 374
- References
- 55
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.